485 results about "Molecular binding" patented technology

Provided herein are methods of detecting single molecules that include binding single molecules in a sample solution to a first surface of an optically transparent substrate include the optically transparent substrate is free of a metallic coating. In some embodiments, the methods include irradiating the first surface of the substrate with an incident light having an incident angle selected to achieve total internal reflection of the incident light, thereby scattering light from the first surface and from the single molecules bound to the surface in which a wavelength of the incident light is between 10 nm and 350 μm and the optically transparent substrate has a refractive index at the wavelength of the incident light exceeding that of the sample solution, and collecting an image that captures interference between evanescent light scattered from the single molecules and the first surface. Systems and additional methods are also provided.

The invention discloses a molecular binding prediction model training method and device, equipment and a storage medium. Relates to the technical field of artificial intelligence. The method comprises the following steps: performing feature extraction on a sequence of a first biomolecule sample through a molecular binding prediction model to obtain a first feature; performing feature extraction on the sequence of the second biomolecule sample through a molecule combination prediction model to obtain a second feature; obtaining an interaction feature based on the first feature and the second feature through a molecular binding prediction model; obtaining a combination probability based on the first feature, the second feature and the interaction feature through a molecular combination prediction model; and adjusting parameters of the molecular binding prediction model based on the binding probability to obtain a trained molecular binding prediction model. By means of the method, the molecular binding prediction model can learn the interaction relation between the sequences of the biomolecules, and then the binding probability between the biomolecules can be predicted more accurately.

Provided herein are methods of performing multiplex detection of ligand binding kinetics. In some embodiments, the methods include contacting ligands with an array of nucleic acid barcoded oscillators disposed on a first surface of a substrate that comprises an electrically conductive coating, applying an AC electric field to the substrate sufficient to induce the nucleic acid barcoded oscillators to oscillate proximal to the first surface of the substrate, and detecting changes in oscillation amplitudes of the nucleic acid barcoded oscillators over a duration to produce sets of ligand binding data. In some embodiments, the methods also include contacting barcode decoding nucleic acids with the array of nucleic acid barcoded oscillators applying an AC electric field to the substrate sufficient to induce the nucleic acid barcoded oscillators to oscillate proximal to the first surface of the substrate, and detecting changes in oscillation amplitudes of the nucleic acid barcoded oscillators over a duration to produce sets of barcode decoding data.

The invention provides a cationic antistatic agent containing hydroxyl and ether bonds and a preparation method thereof, and belongs to the technical field of cationic antistatic agents. The preparation method comprises the following steps: carrying out neutralization reaction on amine substances and acid in a solvent to obtain an intermediate product; and reacting the intermediate product with glycidyl ether under the action of a catalyst to obtain the cationic antistatic agent. According to the prepared cationic antistatic agent, hydroxyl and ether bonds are introduced into the molecular structure, the hygroscopicity of the antistatic agent can be remarkably improved due to the existence of the hydroxyl, a conductive water film is formed, and therefore the conductivity and the antistatic performance of the surface of a material are enhanced; ether bonds can be combined with water molecules in air through hydrogen bonds to form a conductive channel, so that the antistatic effect is further improved. The antistatic agent prepared by the invention not only has excellent antistatic property, but also shows good smoothness, softness, water cleaning property, washing resistance and compatibility, and is suitable for various application scenes needing antistatic treatment.

The technology described herein is directed to targeting molecules that bind to one or more transmembrane molecules expressed in tumor vascular endothelial cells and that are capable of targeting an agent that induces cell death, for example, immunogenic or non-immunogenic cancer cell death. In another aspect, described herein are methods of treating a subject having cancer comprising administering said targeting molecules and agents, and, in certain embodiments, enhancing the immunogenic response to the cancer, for example, by enhancing intratumoral infiltration of T cells.

The invention relates to a UCNPs probe-based in-situ dynamic monitoring molecular interaction method, which comprises: S1, providing a UCNPs probe, the core layer of the UCNPs probe being a rare earth up-conversion nanocrystal, the shell layer of the UCNPs probe being an anti-quenching inert material, and the anti-quenching inert material coating the surface of the rare earth up-conversion nanocrystal; the surface of the anti-quenching inert material is modified with ligand molecules, and the ligand molecules are used for being specifically combined with target molecules in a to-be-detected sample; s2, mixing or contacting the UCNPs probe with a to-be-detected sample containing target molecules to construct a to-be-analyzed molecular interaction system; s3, irradiating the molecular interaction system by adopting near-infrared pulse laser, and collecting the change of the fluorescence lifetime tau of the UCNPs along with the time t and the change of the fluorescence intensity I along with the time t in real time to obtain a tau-t curve and an I-t curve; and S4, according to the tau-t curve and the I-t curve, realizing in-situ dynamic monitoring on the molecular interaction state. According to the method, a molecular binding / dissociation event is directly converted into a quantifiable and anti-interference optical signal, and the technical defect that in-situ dynamic monitoring of molecular interaction cannot be achieved in a traditional technology is overcome.

Described herein are platforms, systems, media, and methods for a machine learning-driven iterative drug discovery process. Some aspects comprise: receiving a first input data set comprising first binding interaction information between a target molecule and a library of compounds; processing the first input data set using a machine learning module to generate a model representation of binding interactions, wherein the representation is configured to predict binding between the target molecule and an input compound; determining an updated library of compounds using the model representation of binding interactions, wherein the updated library of compounds comprises one or more new compounds predicted to bind the target molecule; receiving a second input data set comprising second binding interaction information between the target molecule and the updated library of compounds; and processing the second input data set using the machine learning module to update the model representation of binding interactions, wherein the predictive accuracy of the updated model representation is improved.

The invention discloses a lateral flow chromatography test strip for detecting perfluorooctanoic acid by combining gold nanoparticles, a nucleic acid aptamer and an antibody. According to the test strip, a nucleic acid aptamer marked by gold nanoparticles is combined with PFOA molecules to form a nucleic acid aptamer with a G-quadruplex structure, and then the nucleic acid aptamer with the G-quadruplex structure is specifically recognized and captured by an anti-BG4 antibody, so that specific visual detection of perfluorooctanoic acid is realized. After a sample is injected, a G-quadruplex structure formed by the PFOA and the nucleic acid aptamer acts with the anti-BG4 antibody coated on the test strip, so that the gold nanoparticles are agglomerated to generate a chromogenic reaction, the signal intensity can be detected by naked eyes or reading equipment, the visual detection limit is 10 mu M, and the equipment detection limit is 304 nM. The test strip has the advantages of high detection speed, high specificity and high sensitivity, and is suitable for field detection and rapid screening. Compared with a traditional method, the method realizes simple, convenient and economical detection of PFOA, and has a wide application prospect.

The present invention discloses a method for predicting peptides that are capable of binding to HLA molecules that incorporate the crystal structure of HLA molecules. An improved HLA-specific peptide docking workflow is used to simulate the occupancy of a peptide on the binding pocket of an HLA molecule, and three models are trained to predict the binding of the peptide to HLA molecules. The results show that these models predict HLA-allele specific binding peptides with extremely high accuracy.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The present disclosure relates to a mammalian cell which is modified to express on the surface of its membrane a binding domain which binds to a target molecule. The disclosure also relates to protein constructs and nucleic acids for producing such modified mammalian cells, and to methods for using the mammalian cells to deliver therapeutic agents to target cells or tissues in vivo.

An iRGD-LAMP2B-EGFP fusion protein mediated exosome surface engineering strategy is adopted, through specific recognition of iRGD peptide and integrin alpha v beta 3, corneal neovascularization core lesion cells are actively targeted, the limitation of off-target toxicity of a traditional delivery system is broken through, and a'accurate focus recognition-efficient homing 'targeted delivery normal form is established. Meanwhile, the screened circular RNA with anti-inflammatory and anti-angiogenesis dual activities is used as a core effector molecule, and in combination with an in-situ loading technology of the circular RNA molecule in an exosome parent cell, stable entrapment and targeted release of a nucleic acid drug in an exosome cavity are realized, and the problems that the nucleic acid drug is easy to degrade and poor in targeting property are solved; and dual guarantee of function specificity and delivery stability is formed. And a synergistic treatment system of a targeting exosome carrier and bifunctional circular RNA is further constructed, active molecules are accurately delivered to focus cells, and an inflammation microenvironment and an angiogenesis pathway are synchronously regulated and controlled.

The invention relates to a small molecule detection method. The method comprises the following steps: forming a multi-component compound containing'a first compound antibody-small molecules / small molecule binding partner compound-a second compound antibody ', and detecting the small molecules in a sample by detecting the multi-component compound, the micromolecule binding partner can be specifically bound with micromolecules, has at least two antigen binding sites, and can be bound with at least two micromolecules to obtain the micromolecule / micromolecule binding partner compound. And forming at least two new conformational epitopes different from the small molecule in the free state and the small molecule binding partner in the free state; each of the first complex antibody and the second complex antibody specifically binds to at least one new conformational epitope, and neither the first complex antibody nor the second complex antibody is an antibody of the small molecule antigen nor a specific antibody of the small molecule binding partner.

An exemplary embodiment of the present disclosure provides a composition for identifying a presence of tuberculosis in a subject. The composition comprises a molecule of interest configured to bind with a target molecule in a biological sample; a probe molecule configured to bind with the target molecule; and a metal particle configured to bind with the probe molecule. Another aspect of the present disclosure provides a method of diagnosing diagnosing tuberculosis in a subject. The method comprises combining the composition of the present disclosure with a sample solution comprising the biological sample to form a testing sample, imaging the testing sample, and determining, based on an image of the testing sample, whether the biological sample comprises an active tuberculosis infection.

Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for computationally designing a ligand for binding to a target molecule. In one aspect, a method comprises: obtaining target molecule data characterizing at least a portion of a target molecule; processing a network input comprising the target molecule data using an embedding neural network to generate latent conditioning data representing the target molecule; generating, using a generative model and while the generative model is conditioned on the latent conditioning data representing the target molecule, predicted ligand data defining a predicted ligand that is predicted to bind to the target molecule; and providing the predicted ligand data defining the predicted ligand.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The invention relates to the technical field of bioinformatics, and discloses an iterative feedback type protein targeting molecule intelligent generation method and device, and the method comprises the steps: obtaining molecular structure data, training based on the molecular structure data to obtain a molecular fragment language model, and the molecular fragment language model is used for predicting subsequent molecular fragments according to an input molecular fragment sequence; obtaining an attribute preference data set, and performing alignment fine tuning on the pre-trained molecular fragment language model based on the attribute preference data set to obtain an attribute preference alignment model; and obtaining target structure information of the target protein, taking the attribute preference alignment model as a strategy network, iteratively generating and evaluating candidate molecules through a tree search algorithm under the constraint of the target structure information until a termination condition is met, and outputting the optimized protein targeting molecules. According to the application, excellent pharmacological properties can be taken into account while the protein targeting molecule binding effect is ensured, and the molecule generation quality can be dynamically optimized.

The invention belongs to the technical field of protein function prediction, and relates to a recognition system for a natural disordered functional region. The system receives a protein sequence, converts the protein sequence into a sequence representation vector based on a protein language model, and outputs the sequence representation vector to a disordered binding region prediction model and a flexible connection region prediction model respectively. The disordered binding region prediction model is composed of a multi-scale feature processing module and a multifunctional classifier, and the disordered binding region and the binding molecule type thereof are speculated by predicting the probability that each residue in the sequence is located in a disordered region and is bound with five types of molecules including protein, nucleic acid and the like. The flexible connection region prediction model is composed of a single feature processing module and a single classifier, and can predict the probability that each residue in the sequence is located in the flexible connection region. The method has the beneficial effects that on a blind test data set provided by the natural disordered protein and the function prediction evaluation platform CAID of the natural disordered protein, the prediction precision is in the front, so that the method can realize accurate prediction of the disordered functional region.

The present invention relates to a polypeptide for delivering an antigen to an immune cell, and more specifically, to a novel polypeptide comprising a cell membrane-permeable peptide and a peptide that binds to a surface molecule of an immune cell, a fusion polypeptide in which an antigen is bound to the polypeptide, a nucleic acid encoding the polypeptide or the fusion polypeptide, an immune cell sensitized with the fusion polypeptide or a nucleic acid encoding the same, an immunotherapeutic agent comprising the immune cell, an anti-tumor or anti-cancer vaccine, and a composition for treating a tumor or cancer.

In one aspect, the disclosure relates to compounds methods for treating or preventing diseases associated with aberrant condensation of a biomolecule in a subject, the method including at least the step of contacting one or more cells in the subject with a fusion protein that includes a J domain protein and a targeting molecule, wherein the targeting molecule binds the biomolecule. In one aspect, the biomolecule can be a target protein that may be mutated and / or include one or more intrinsically disordered regions. In another aspect, the targeting molecule can be a nanobody, but other targeting molecules are also contemplated. In still another aspect, the disclosed method is useful for treating and / or preventing cancers such as blood cancers and non-small cell lung cancer. Also disclosed are methods for disrupting condensates in cell culture.

The present disclosure relates to T-cell receptors (TCRs) that bind to tumor-associated antigens (TAA) for targeting cancer cells, T-cells expressing them, methods for producing them, and methods for treating cancers using them. In particular, the present disclosure relates to TCRs and variants thereof that bind to HLA class I or II molecules with a peptide, such as IGF2BP3-001 having the amino acid sequence KIQEILTQV (SEQ ID NO:1). The present disclosure further relates to peptides, proteins, nucleic acids, and cells for use in immunotherapeutic methods. In particular, the present disclosure relates to cancer immunotherapy.The present disclosure further relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides, which can for example serve as active pharmaceutical ingredients in vaccine compositions that stimulate anti-tumor immune responses or stimulate T-cells ex vivo and deliver them to patients. Peptides bound to major histocompatibility complex (MHC) molecules, or the peptides themselves, can also be targets of antibodies, soluble T-cell J receptors and other binding molecules.

The present invention relates to the technical field of in-vitro testing, and in particular to a method for using a sandwich method to test a target molecule in a sample. The present invention provides a method for testing a target molecule in a sample under test, and testing is mainly performed by mean of a sandwich method, greatly improving the accuracy of testing of small molecules in serum. According to the method in the present invention, a complex-specific antibody specifically binding to a target molecule-target molecule binding protein is utilized to form a target molecule-target molecule binding protein-antibody ternary complex for testing. When a blood / serum sample containing the target molecule-target molecule binding protein is tested, in the method in the present invention, firstly, a specific dissociation solution is utilized to treat the sample under test so as to dissociate the target molecule from the target molecule-target molecule binding protein complex in the sample under test, so that the accuracy of testing of the target molecule can be further improved.

The present invention provides molecules that bind to cellular components or parts thereof (e.g., filaments or histones forming the cytoskeleton or nucleoskeleton) that are exposed to the extracellular environment upon cell death, which are specifically observed in diseased tissues, and simultaneously bind to target molecules on or in cells that act specifically in tissues where cell death is observed, such as diseased tissues, abnormal tissues, etc. The molecules of the present invention are useful as drugs that provide significant therapeutic or preventive effects while reducing side effects.

A non-human animal is genetically modified with sequence encoding a human or humanized MHC molecule or associated molecule, e.g., β2 microglobulin, and expression of the sequence by the non-human animal induces tolerance to the corresponding human HLA from which the human or human MHC molecule is derived. The tolerance exhibited by these non-human animals allows these animals to generate specific antibody responses to the corresponding human HLA when such HLA is presenting a peptide that is antigenic to the non-human animal. Such an antibody response, which specifically targets a pMHC complex of interest without binding to the MHC molecule may be useful in immunotherapeutic modalities that target a component of the immunological synapse which provides the specificity of that interaction.

Bispecific binding molecules are disclosed that bind to human MUC16 and human death receptor 5, and can kill cancer cells expressing MUC16 and death receptor 5. Also disclosed are pharmaceutical compositions comprising these antibodies, and methods of treatment for using these antibodies.

The present invention provides a method for screening for a candidate peptide capable of binding to a target molecule, the method including the steps of: (1) preparing a plurality of nucleic acid display libraries containing a barcoded peptide-nucleic acid complex, wherein the barcoded peptide-nucleic acid complex contains a nucleic acid moiety and a peptide moiety, the nucleic acid moiety contains a barcode sequence and a nucleic acid sequence encoding the peptide, and the plurality of nucleic acid display libraries are nucleic acid display libraries, each of which is independently produced by translation using a cell-free translation system; (2) mixing the plurality of nucleic acid display libraries to prepare a mixed nucleic acid display library; (3) bringing the mixed nucleic acid display library into contact with the target molecule; and (4) amplifying a nucleic acid corresponding to the nucleic acid moiety of the barcoded peptide-nucleic acid complex bound to the target molecule, using a barcode primer.

The present invention relates to a method for using an optionally alkoxylated nitrogen-containing polymer in the capture of carbon dioxide, said optionally alkoxylated nitrogen-containing polymer comprising the following steps: a) a step of reacting (i) a di- or oligoamine (A) with (ii) a crosslinking compound (BC) to provide a nitrogen-containing polymer (NP), wherein the crosslinking compound (BC) is (I) phosgene; or (II) comprises at least two amine-reactive groups (ARG), the crosslinking compound (BC) being capable of binding to the amine groups of at least two di- or oligoamine (A) molecules, the nitrogen-containing polymer (NP) comprising the molecular components of the crosslinking compound (BC) that bind to at least two molecular components of the di- or oligoamine (A), the proportion of the crosslinking compound (BC) molecules bound to at least two di- or oligoamine (A) molecules being the crosslinking factor (BF) of the nitrogen-containing polymer (NP), the crosslinking factor (BF) exceeding 50%, the sum of the primary and secondary amine groups of the nitrogen-containing polymer (NP) being at least 600 mg KOH / g, the number average molecular weight (Mn) of the nitrogen-containing polymer (NP) exceeding 600 g / mol, and b) a step of reacting the nitrogen-containing polymer (NP) with an alkylene oxide (AO), wherein the molar ratio of the alkylene oxide (AO) to the NH functionality of the nitrogen-containing polymer (NP) is 0.25 or less, obtainable by a method comprising. The present invention further relates to a method for capturing carbon dioxide from a gas mixture using an optionally alkoxylated nitrogen-containing polymer.

Provided herein are components for antigen-binding constructs, including antibodies and fragments thereof, such as minibodies and cys-diabodies, that bind to target molecules, e.g., DLL3. In some embodiments, these components are novel complementarity-determining region (CDR) sequences and / or sequences related to and / or portions of CDR sequences. In some embodiments, these components are novel framework region (FR) sequences and / or sequences related to and / or portions of FR sequences. These CDR and FR sequences may provide various benefits. Also provided herein are antigen-binding constructs (minibodies, cys-diabodies, etc.) that include one or more of the CDR or FR sequences or subsequences provided herein.

Described herein is an isolated cell comprising a recombinant T cell receptor (TCR) and a TCR pathway-dependent reporter, wherein the recombinant T cell receptor is specific for a disease-associated antigen bound to an MHC molecule. Also described is an assay for the isolated cell for determining the function or efficacy of a peptide-major histocompatibility complex (pMHC) (pMHC-NP) coupled to a nanoparticle, which can be used as a drug for treating autoimmune diseases or cancer.

This application provides a method for screening inhibitors targeting CYP7A1 and their use in the preparation of anti-liver cancer drugs, relating to the field of tumor targeted drug design technology. The method for screening inhibitors targeting CYP7A1 protein includes: using the crystal structure of human cholesterol 7α-hydroxylase as a receptor model, precise docking screening is performed using software to screen drug-like molecules with molecular weights of 250-500 Da and lipid-water partition coefficients of -1 to 5 from a compound database; a graph neural network active learning model is used to predict and rank the protein-small molecule binding affinity of compounds in the database; the ΔG between candidate molecules and CYP7A1 is calculated using molecular mechanics / generalized Born surface area methods, with molecules having ΔG ≤ -40 kcal / mol considered potential inhibitors. The inhibitors of this application do not rely on the enzymatic activity of CYP7A1 to achieve anti-tumor effects and do not significantly affect cholesterol and bile acid metabolism levels.